A Phase 3 interventional study of REL-1017 and Placebo in Major Depressive Disorder and Depression, sponsored by Levomecor Inc.. Terminated at 70 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Levomecor Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 308th largest by enrollment of the 1,323 interventional ones that give a count, is one of 72 that started in 2021, is one of 240 in phase 3, and was the 1,121st registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 22–60
Baylor College of Medicine · Sites in United States
Ages 18–64
Ohio State University · Sites in United States
Ages 21–65
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 325 · Phase 3 262 · Phase 4 189
First in 1979; this study’s year is marked. 72 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 236 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 1,323 interventional studies, 100 across the 171 observational. Of the 1,156 that completed or were terminated, 584 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
484 of 1,500 have an industry lead sponsor. The 10 most frequent:
Levomecor Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Levomecor Inc. has 2 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
99 of the studies in Depressive Disorder, Major with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 99 to your calendar (.ics) → With an account.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug or placebo for the duration of the treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the double blind treatment period (28 days), participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT)
Drug: REL-1017
During the double blind treatment period (28 days), participants will take 1 tablet of placebo, orally, per day in addition to their ongoing antidepressant (ADT).
Drug: Placebo
REL-1017 tablet
Also known as: Esmethadone
Placebo tablet
Change From Baseline to Day 28 in MADRS Total Score
Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. The total score is calculated as the sum of 10 items, each scored from 0 to 6, resulting in a total score range of 0 to 60. Lower scores indicate less severe depressive symptoms and a better outcome, whereas higher scores indicate more severe depressive symptoms and a worse outcome. The outcome measure reports the change in MADRS total score from Baseline to Day 28. Change was calculated as Day 28 score minus Baseline score.
Time frame: Baseline and Day 28
Change From Baseline to Day 7 in MADRS Total Score
Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. The total score is calculated as the sum of 10 items, each scored from 0 to 6, resulting in a total score range of 0 to 60. Lower scores indicate less severe depressive symptoms and a better outcome, whereas higher scores indicate more severe depressive symptoms and a worse outcome. The outcome measure reports the change in MADRS total score from Baseline to Day 7. Change was calculated as Day 7 score minus Baseline score.
Time frame: Day 7
Change From Baseline to Day 28 in Clinical Global Impression-Severity (CGI-S) Score
Clinical Global Impression-Severity (CGI-S) is a clinician-rated assessment of illness severity. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Lower scores indicate less severe illness and a better outcome, whereas higher scores indicate more severe illness and a worse outcome. The outcome measure reports the change in CGI-S score from Baseline to Day 28. Change was calculated as Day 28 score minus Baseline score
Time frame: Day 28
MADRS10 Remission Rate at Day 28
Remission was defined as a Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score ≤10 at Day 28. The MADRS total score ranges from 0 to 60, with lower scores indicating less severe depressive symptoms and a better outcome.
Time frame: Day 28
MADRS10 Response Rate at Day 28
Response was defined as a ≥50% reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS total score ranges from 0 to 60, with lower scores indicating less severe depressive symptoms and a better outcome.
Time frame: Day 28
| Milestone | REL-1017 | Placebo |
|---|---|---|
| Started | 119 | 117 |
| Completed | 110 | 109 |
| Not completed | 9 | 8 |
Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. The total score is calculated as the sum of 10 items, each scored from 0 to 6, resulting in a total score range of 0 to 60. Lower scores indicate less severe depressive symptoms and a better outcome, whereas higher scores indicate more severe depressive symptoms and a worse outcome. The outcome measure reports the change in MADRS total score from Baseline to Day 28. Change was calculated as Day 28 score minus Baseline score.
| Scores on a scale (MADRS10) | REL-1017 | Placebo |
|---|---|---|
| Change From Baseline to Day 28 in MADRS Total Score | -14.81 ± 1.00 | -13.9 ± 1.01 |
Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. The total score is calculated as the sum of 10 items, each scored from 0 to 6, resulting in a total score range of 0 to 60. Lower scores indicate less severe depressive symptoms and a better outcome, whereas higher scores indicate more severe depressive symptoms and a worse outcome. The outcome measure reports the change in MADRS total score from Baseline to Day 7. Change was calculated as Day 7 score minus Baseline score.
| Scores on a scale (MADRS10) | REL-1017 | Placebo |
|---|---|---|
| Change From Baseline to Day 7 in MADRS Total Score | -9.66 ± 0.77 | -7.02 ± 0.78 |
Clinical Global Impression-Severity (CGI-S) is a clinician-rated assessment of illness severity. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Lower scores indicate less severe illness and a better outcome, whereas higher scores indicate more severe illness and a worse outcome. The outcome measure reports the change in CGI-S score from Baseline to Day 28. Change was calculated as Day 28 score minus Baseline score
| Scores on a scale (CGI-S) | REL-1017 | Placebo |
|---|---|---|
| CGI-S Day 28 | -1.36 ± 0.11 | -1.24 ± 0.11 |
| CGI-S Day 7 | -0.74 ± 0.08 | -0.48 ± 0.08 |
Remission was defined as a Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score ≤10 at Day 28. The MADRS total score ranges from 0 to 60, with lower scores indicating less severe depressive symptoms and a better outcome.
| Participants | REL-1017 | Placebo |
|---|---|---|
| MADRS10 Remission Rate at Day 28 | 34 | 23 |
Response was defined as a ≥50% reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS total score ranges from 0 to 60, with lower scores indicating less severe depressive symptoms and a better outcome.
| Participants | REL-1017 | Placebo |
|---|---|---|
| MADRS10 Response Rate Day 28 | 51 | 45 |
| MADRS10 Response Rate Day 7 | 25 | 13 |
Collected over TEAE that starts or worsens at any time after initiation of study drug collected up to 14 days post treatment (Day 42).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| REL-1017 | 0/119 (0%) | 0/119 (0%) | 47/119 (39.5%) |
| Placebo | 0/117 (0%) | 0/117 (0%) | 57/117 (48.7%) |
| Event | REL-1017 | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 5/119 | 9/117 |
| NauseaGastrointestinal disorders | 3/119 | 5/117 |
| InsomniaPsychiatric disorders | 2/119 | 5/117 |
| PalpitationsCardiac disorders | 1/119 | 5/117 |
| DizzinessNervous system disorders | 3/119 | 4/117 |
| DiarrhoeaGastrointestinal disorders | 3/119 | 4/117 |
| COVID-19Infections and infestations | 2/119 | 4/117 |
| SonnolenceNervous system disorders | 4/119 | 1/117 |
| Upper respiratory tract infectionInfections and infestations | 4/119 | 1/117 |
| FatigueGeneral disorders | 4/119 | 3/117 |
| Age, Categorical(Participants) | REL-1017 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 119 | 117 | 236 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | REL-1017 | Placebo | Total |
|---|---|---|---|
| Female | 89 | 84 | 173 |
| Male | 30 | 33 | 63 |
| Race (NIH/OMB)(Participants) | REL-1017 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 3 | 4 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 15 | 12 | 27 |
| White | 97 | 97 | 194 |
| More than one race | 4 | 3 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | REL-1017 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 24 | 33 | 57 |
| Not Hispanic or Latino | 93 | 80 | 173 |
| Unknown or Not Reported | 2 | 4 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2021 to primary completion in Dec 2024, 45 months.
Results were first posted in Jul 2026, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: D-methadone
Levomecor Inc.